Literature DB >> 28825047

Consensus Molecular Subtypes of Colorectal Cancer and their Clinical Implications.

Ketan Thanki1, Michael E Nicholls1, Aakash Gajjar1, Anthony J Senagore1, Suimin Qiu2, Csaba Szabo3, Mark R Hellmich1, Celia Chao1.   

Abstract

The colorectal cancer (CRC) Subtyping Consortium has unified six independent molecular classification systems, based on gene expression data, into a single consensus system with four distinct groups, known as the Consensus Molecular Subtypes (CMS); clinical implications are discussed in this review. This article is based on a literature review relevant to the CMS of CRC indexed in PubMed (US National Library of Medicine) as well as the authors' own published data. The CMS were determined and correlated with epigenomic, transcriptomic, microenvironmental, genetic, prognostic and clinical characteristics. The CMS1 subtype is immunogenic and hypermutated. CMS2 tumors are activated by the WNT-β-catenin pathway and have the highest overall survival. CMS3 feature a metabolic cancer phenotype and CMS4 cancers have the worst survival and have a strong stromal gene signature. The Consensus Molecular Subtypes of CRC may better inform clinicians of prognosis, therapeutic response, and potential novel therapeutic strategies.

Entities:  

Keywords:  classification; clinical; colorectal cancer; molecular subtypes

Year:  2017        PMID： 28825047      PMCID： PMC5557054     

Source DB:  PubMed          Journal:  Int Biol Biomed J        ISSN： 2423-4478


  30 in total

1.  Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.

Authors:  E Élez; I Kocáková; T Höhler; U M Martens; C Bokemeyer; E Van Cutsem; B Melichar; M Smakal; T Csőszi; E Topuzov; R Orlova; S Tjulandin; F Rivera; J Straub; R Bruns; S Quaratino; J Tabernero
Journal:  Ann Oncol       Date:  2014-10-15       Impact factor: 32.976

2.  Tumor-derived hydrogen sulfide, produced by cystathionine-β-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer.

Authors:  Csaba Szabo; Ciro Coletta; Celia Chao; Katalin Módis; Bartosz Szczesny; Andreas Papapetropoulos; Mark R Hellmich
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-08       Impact factor: 11.205

3.  Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

Authors:  H Blons; J F Emile; K Le Malicot; C Julié; A Zaanan; J Tabernero; E Mini; G Folprecht; J L Van Laethem; J Thaler; J Bridgewater; L Nørgård-Petersen; E Van Cutsem; C Lepage; M A Zawadi; R Salazar; P Laurent-Puig; J Taieb
Journal:  Ann Oncol       Date:  2014-10-06       Impact factor: 32.976

4.  A colorectal cancer classification system that associates cellular phenotype and responses to therapy.

Authors:  Anguraj Sadanandam; Costas A Lyssiotis; Krisztian Homicsko; Eric A Collisson; William J Gibb; Stephan Wullschleger; Liliane C Gonzalez Ostos; William A Lannon; Carsten Grotzinger; Maguy Del Rio; Benoit Lhermitte; Adam B Olshen; Bertram Wiedenmann; Lewis C Cantley; Joe W Gray; Douglas Hanahan
Journal:  Nat Med       Date:  2013-04-14       Impact factor: 53.440

5.  Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.

Authors:  Patrick G Gavin; Linda H Colangelo; Debora Fumagalli; Noriko Tanaka; Matthew Y Remillard; Greg Yothers; Chungyeul Kim; Yusuke Taniyama; Seung Il Kim; Hyun Joo Choi; Nicole L Blackmon; Corey Lipchik; Nicholas J Petrelli; Michael J O'Connell; Norman Wolmark; Soonmyung Paik; Kay L Pogue-Geile
Journal:  Clin Cancer Res       Date:  2012-10-08       Impact factor: 12.531

6.  Cystathionine-beta-synthase inhibition for colon cancer: Enhancement of the efficacy of aminooxyacetic acid via the prodrug approach.

Authors:  Celia Chao; John R Zatarain; Ye Ding; Ciro Coletta; Amy A Mrazek; Nadiya Druzhyna; Paul Johnson; Haiying Chen; Judy L Hellmich; Antonia Asimakopoulou; Kazunori Yanagi; Gabor Olah; Petra Szoleczky; Gabor Törö; Fredrick J Bohanon; Minal Cheema; Rachel Lewis; David Eckelbarger; Akbar Ahmad; Katalin Módis; Ashley Untereiner; Bartosz Szczesny; Andreas Papapetropoulos; Jia Zhou; Mark R Hellmich; Csaba Szabo
Journal:  Mol Med       Date:  2016-05-16       Impact factor: 6.354

7.  Comprehensive molecular characterization of human colon and rectal cancer.

Authors: 
Journal:  Nature       Date:  2012-07-18       Impact factor: 49.962

8.  Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition.

Authors:  Paul Roepman; Andreas Schlicker; Josep Tabernero; Ian Majewski; Sun Tian; Victor Moreno; Mireille H Snel; Christine M Chresta; Robert Rosenberg; Ulrich Nitsche; Teresa Macarulla; Gabriel Capella; Ramon Salazar; George Orphanides; Lodewyk F A Wessels; Rene Bernards; Iris M Simon
Journal:  Int J Cancer       Date:  2013-09-13       Impact factor: 7.396

9.  Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.

Authors:  Laetitia Marisa; Aurélien de Reyniès; Alex Duval; Janick Selves; Marie Pierre Gaub; Laure Vescovo; Marie-Christine Etienne-Grimaldi; Renaud Schiappa; Dominique Guenot; Mira Ayadi; Sylvain Kirzin; Maurice Chazal; Jean-François Fléjou; Daniel Benchimol; Anne Berger; Arnaud Lagarde; Erwan Pencreach; Françoise Piard; Dominique Elias; Yann Parc; Sylviane Olschwang; Gérard Milano; Pierre Laurent-Puig; Valérie Boige
Journal:  PLoS Med       Date:  2013-05-21       Impact factor: 11.069

10.  Current clinical trials testing the combination of immunotherapy with radiotherapy.

Authors:  Josephine Kang; Sandra Demaria; Silvia Formenti
Journal:  J Immunother Cancer       Date:  2016-09-20       Impact factor: 13.751
View more
  41 in total

1.  Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer.

Authors:  Hae-Ock Lee; Yourae Hong; Hakki Emre Etlioglu; Yong Beom Cho; Valentina Pomella; Ben Van den Bosch; Jasper Vanhecke; Sara Verbandt; Hyekyung Hong; Jae-Woong Min; Nayoung Kim; Hye Hyeon Eum; Junbin Qian; Bram Boeckx; Diether Lambrechts; Petros Tsantoulis; Gert De Hertogh; Woosung Chung; Taeseob Lee; Minae An; Hyun-Tae Shin; Je-Gun Joung; Min-Hyeok Jung; Gunhwan Ko; Pratyaksha Wirapati; Seok Hyung Kim; Hee Cheol Kim; Seong Hyeon Yun; Iain Bee Huat Tan; Bobby Ranjan; Woo Yong Lee; Tae-You Kim; Jung Kyoon Choi; Young-Joon Kim; Shyam Prabhakar; Sabine Tejpar; Woong-Yang Park
Journal:  Nat Genet       Date:  2020-05-25       Impact factor: 38.330

2.  Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry.

Authors:  Li Chia Chong; Amanda Rose Townsend; Joanne Young; Amitesh Roy; Cynthia Piantadosi; Jennifer E Hardingham; David Roder; Christos Karapetis; Robert Padbury; Guy Maddern; James Moore; Timothy Jay Price
Journal:  Target Oncol       Date:  2019-02       Impact factor: 4.493

3.  Molecular Pathogenesis and Classification of Colorectal Carcinoma.

Authors:  Anup Kasi; Shivani Handa; Sajjad Bhatti; Shahid Umar; Ajay Bansal; Weijing Sun
Journal:  Curr Colorectal Cancer Rep       Date:  2020-08-15

4.  Association of Epigenetic Clock with Consensus Molecular Subtypes and Overall Survival of Colorectal Cancer.

Authors:  Chunlei Zheng; Li Li; Rong Xu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-08-02       Impact factor: 4.254

5.  Effects of Chemotherapy for Metastatic Colorectal Cancer on the TGF-β Signaling and Related miRNAs hsa-miR-17-5p, hsa-miR-21-5p and hsa-miR-93-5p.

Authors:  Jovana Despotovic; Sandra Dragicevic; Aleksandra Nikolic
Journal:  Cell Biochem Biophys       Date:  2021-04-07       Impact factor: 2.194

6.  Immune Responses Vary in Preinvasive Colorectal Lesions by Tumor Location and Histology.

Authors:  Kristin Wallace; Georges J El Nahas; Christine Bookhout; Jessica E Thaxton; David N Lewin; Nana Nikolaishvili-Feinberg; Stephanie M Cohen; J Grant Brazeal; Elizabeth G Hill; Jennifer D Wu; John A Baron; Alexander V Alekseyenko
Journal:  Cancer Prev Res (Phila)       Date:  2021-08-02

7.  Claudin-Low Breast Cancer Inflammatory Signatures Support Polarization of M1-Like Macrophages with Protumoral Activity.

Authors:  Mayra Cecilia Suárez-Arriaga; Alfonso Méndez-Tenorio; Vadim Pérez-Koldenkova; Ezequiel M Fuentes-Pananá
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

Review 8.  Metabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy.

Authors:  Miljana Nenkov; Yunxia Ma; Nikolaus Gaßler; Yuan Chen
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

9.  A novel mesenchymal-associated transcriptomic signature for risk-stratification and therapeutic response prediction in colorectal cancer.

Authors:  Takatoshi Matsuyama; Raju Kandimalla; Toshiaki Ishikawa; Naoki Takahashi; Yasuhide Yamada; Masamichi Yasuno; Yusuke Kinugasa; Torben Frøstrup Hansen; Marwan Fakih; Hiroyuki Uetake; Balázs Győrffy; Ajay Goel
Journal:  Int J Cancer       Date:  2020-07-13       Impact factor: 7.316

Review 10.  Microsatellite instability in colorectal cancer.

Authors:  Jafar Nouri Nojadeh; Shahin Behrouz Sharif; Ebrahim Sakhinia
Journal:  EXCLI J       Date:  2018-01-22       Impact factor: 4.068
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.